AXIM (AXIM Biotechnologies) Gross Margin % : 94.12% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AXIM Biotechnologies's Gross Profit for the three months ended in Jun. 2024 was $0.02 Mil. AXIM Biotechnologies's Revenue for the three months ended in Jun. 2024 was $0.02 Mil. Therefore, AXIM Biotechnologies's Gross Margin % for the quarter that ended in Jun. 2024 was 94.12%.

The historical rank and industry rank for AXIM Biotechnologies's Gross Margin % or its related term are showing as below:

AXIM' s Gross Margin % Range Over the Past 10 Years
Min: -227.66 Med: 4.19 Max: 98.93
Current: 98.93

During the past 13 years, the highest Gross Margin % of AXIM Biotechnologies was 98.93%. The lowest was -227.66%. And the median was 4.19%.

AXIM's Gross Margin % is ranked better than
97.57% of 741 companies
in the Biotechnology industry
Industry Median: 59.96 vs AXIM: 98.93

AXIM Biotechnologies had a gross margin of 94.12% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AXIM Biotechnologies was 0.00% per year.

AXIM Biotechnologies Gross Margin % Historical Data

The historical data trend for AXIM Biotechnologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Gross Margin % Chart

AXIM Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

AXIM Biotechnologies Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	94.12

Competitive Comparison of AXIM Biotechnologies's Gross Margin %

For the Biotechnology subindustry, AXIM Biotechnologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Gross Margin % falls into.

Save Embed

;

Save Embed

;

AXIM Biotechnologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AXIM Biotechnologies's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	0	/	0.04
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.04 - 0)	/	0.04
	=	N/A %

AXIM Biotechnologies's Gross Margin for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )	=	Gross Profit (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	0	/	0.017
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.017 - 0.001)	/	0.017
	=	94.12 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

AXIM Biotechnologies (OTCPK:AXIM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AXIM Biotechnologies had a gross margin of 94.12% for the quarter that ended in Jun. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

AXIM Biotechnologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AXIM Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121

Website

https://www.aximbiotech.com

AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

Executives

Kurt Phinney	officer: Chief Operating Officer	6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke	director	C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp	10 percent owner	5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii	director	305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek	officer: CFO	PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc.	10 percent owner	12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022